Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Northstar Gold Signs MOU with Hunan Nonferrous Ltd. to Develop Gold Resource (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Xenetic Biosciences Inc XBIO

Healthcare Biotechnology
Xenetic Biosciences, Inc. is a biopharmaceutical company. The Company is focused on advancing immune-oncology technologies addressing hard to treat cancers. The Company's DNase platform is designed to improve outcomes of existing treatments, including immunotherapies, by targeting neutrophil extracellular traps (NETs), which are involved in cancer progression. It is focused on advancing the... see more

Recent & Breaking News (NDAQ:XBIO)

Xenetic Biosciences, Inc. Engages Leading NETs Research Expert, Jonathan Spicer, MD, PhD for Advancement of DNase Oncology Platform

Accesswire November 16, 2022

Xenetic Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update

Accesswire November 10, 2022

Xenetic Biosciences, Inc. Announces Signing of Patent Assignment Related to Collaboration With VolitionRx Limited and CLS Therapeutics

Accesswire October 11, 2022

Xenetic Biosciences, Inc. Appoints Globally Recognized Oncology Leader, Allan Tsung, MD to its Scientific Advisory Board

Accesswire October 4, 2022

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 24th Annual Global Investment Conference

Accesswire September 7, 2022

Xenetic Biosciences, Inc. Reports Second Quarter 2022 Financial Results and Provides Business Update

Accesswire August 12, 2022

Xenetic Biosciences, Inc. and VolitionRx Limited Collaborate to Develop NETs-Targeted Adoptive Cell Therapies for the Treatment of Cancer

Accesswire August 2, 2022

Xenetic Biosciences, Inc. Engages Catalent for Clinical Manufacturing to Advance DNase-Based Oncology Platform Towards Phase 1 Study

Accesswire July 7, 2022

JTC Team to Host Virtual Investor Innovation in Oncology Featuring Xenetic Biosciences

Accesswire June 2, 2022

Xenetic Biosciences, Inc. to Participate in the Virtual Investor Innovation in Oncology Event

Accesswire June 2, 2022

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright Global Investment Conference

Accesswire May 18, 2022

Xenetic Biosciences, Inc. Reports First Quarter 2022 Financial Results and Provides Business Update

Accesswire May 12, 2022

Xenetic Biosciences, Inc. Expands Oncology Pipeline with In-Licensing of DNase Based Oncology Platform Comprising Multiple Therapeutic Modalities

Accesswire April 27, 2022

Xenetic Biosciences, Inc. Reports Full Year 2021 Financial Results and Provides Business Update

Accesswire March 23, 2022

Xenetic Biosciences, Inc. Reports Third Quarter 2021 Financial Results and Provides Business Update

Accesswire November 12, 2021

Xenetic Biosciences, Inc. Receives Notice of Allowance for XCART(TM) Patent

Accesswire September 9, 2021

Xenetic Biosciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Conference

Accesswire September 8, 2021

Xenetic Biosciences, Inc. Reports Second Quarter 2021 Financial Results and Provides Business Update

Accesswire August 13, 2021

Xenetic Biosciences, Inc. Announces Closing of $12.5 Million Private Placement Priced at a Premium to Market

Accesswire July 28, 2021

Xenetic Biosciences, Inc. Announces $12.5 Million Private Placement Priced at a Premium to Market

Accesswire July 26, 2021